Airway Allergy Research



Clinical Safety and Tolerability of gpASIT+TM Administered Subcutaneously in Absence or in Presence of DnaK Immunoregulating Adjuvant for the Prophylaxis of Seasonal Grass Pollen Rhinoconjunctivitis | Randomised, doubleblind, placebo-controlled study. Trial is registered on with number NCT01111279. | Clinic: Jan Ceuppens Mechanistic: Mohamed Shamji



Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients | Interventional Phase II study. Trial is registered on with number NCT02156791 | Clinic: Bettina Hauswald - Mechanistic: Mohamed Shamji



A prospective, randomized, double-blind placebo-controlled multi-centre dose-finding study of 3 different regimens of gpASIT+TM administered subcutaneously to adult patients with grass pollen-induced allergic rhinoconjunctivitis. | randomized, double-blind placebo-controlled multi-centre Phase IIb study. Trial is registered on with number 2013-005445-37 | Clinic: Ralph Mosges Mechanistic: Mohamed Shamji


Grass allergen immunotherapy

Protocol for randomised, double blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis | Randomised, double-blind, placebo-controlled study ,trial is registered with with trial number NCT02005627 | Professor Stephen Durham

Submit your Research

Click here to submit your research.


Become a BSACI Member...

GPs, Nurses, Allergy Specialists, Dieticians, Generalists

Join BSACI to receive the regular BSACI Allergy Update, have online access to the monthly journal 'Clinical & Experimental Allergy’, download our popular guidelines and a discount to the BSACI Annual Meeting.

Join Now
* Required
General Paediatrician
A&E Doctor
Specialist Doctor in Allergy
Specialist Allergy Nurse
Paediatric Nurse
Nurse (other)
Allergy Dietitian
Dietitian (other)
Other role